16 analysts have shared their evaluations of Gilead Sciences (NASDAQ:GILD) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...

Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Just Released: Zacks Top 10 Stocks for 2025 Hurry – you can ...

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (SNSE:GILD) from Hold to Buy. There are 3,043 funds or institutions reporting positions in Gilead ...

Investors should consider the style scores a valuable tool that can help you to pick the most appropriate Zacks Rank stocks based on their individual investment style. Gilead has a Value Score of A.

Below is a chart showing VRT's trailing twelve month trading history, with the $85 strike highlighted in orange: Gilead Sciences Inc (Symbol: GILD) saw options trading volume of 40,770 contracts ...

(RTTNews) - Gilead Sciences (GILD ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Gilead Sciences, Inc. GILD announced that the FDA has accepted ...

Andrew D Dickinson, the Chief Financial Officer of $GILD, sold 2,500 shares of the company on 02-18-2025 for an estimated $260,225. We received data on the trade from ...